

# Ali Afshar-Oromieh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4546379/publications.pdf>

Version: 2024-02-01

85  
papers

7,919  
citations

109264

35  
h-index

60583

81  
g-index

92  
all docs

92  
docs citations

92  
times ranked

4989  
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard. <i>Journal of Nuclear Medicine</i> , 2022, 63, 476-484.	2.8	123
2	Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4252-4261.	3.3	22
3	First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1997-2009.	3.3	45
4	Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2436-2444.	3.3	19
5	Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. <i>Cancer Letters</i> , 2022, 530, 156-169.	3.2	49
6	EARL compliance measurements on the biograph vision Quadra PET/CT system with a long axial field of view. <i>EJNMMI Physics</i> , 2022, 9, 26.	1.3	11
7	Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer: a single-centre experience of PET-guided biopsies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3910-3916.	3.3	18
8	PBPK-Adapted Deep Learning for Voxel-Wise Organ Dosimetry Prediction. <i>World Journal of Nuclear Medicine</i> , 2022, , .	0.3	0
9	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 143-151.	3.3	25
10	Extended perfusion defects in lung perfusion-SPECT/CT in a case of fatal COVID-19 pneumonia. <i>Nuklearmedizin - Nuclear Medicine</i> , 2021, 60, 249-251.	0.3	2
11	The influence of colour scale in lesion detection and patient-based sensitivity in [68Ga]Ga-PSMA-PET/CT. <i>Nuclear Medicine Communications</i> , 2021, 42, 495-502.	0.5	5
12	Combination of Forced Diuresis with Additional Late Imaging in <sup>68</sup> Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1252-1257.	2.8	26
13	Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2978-2989.	3.3	58
14	Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy: a multi-centre evaluation of 2533 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2925-2934.	3.3	43
15	Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2395-2404.	3.3	126
16	The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. <i>European Radiology</i> , 2021, 31, 8030-8039.	2.3	19
17	A comprehensive review of imaging findings in COVID-19 - status in early 2021. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2500-2524.	3.3	31
18	Authors' reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2307-2308.	3.3	0

#	ARTICLE	IF	CITATIONS
19	Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer—first clinical experiences. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4456-4462.	3.3	25
20	Prostate Cancer Theranostics. <i>PET Clinics</i> , 2021, 16, 391-396.	1.5	11
21	Prostate Cancer Theranostics. <i>PET Clinics</i> , 2021, 16, 383-390.	1.5	2
22	Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. <i>Cancers</i> , 2021, 13, 3429.	1.7	8
23	Cystic Hepatic Neuroendocrine Tumor. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e577-e578.	0.7	1
24	New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. <i>Pharmaceuticals</i> , 2021, 14, 1023.	1.7	38
25	FDG uptake in axillary lymph nodes after COVID-19 vaccination — a pitfall in a case of highly suspicious lymph node metastases of malignant melanoma. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 456-457.	0.3	1
26	Radiolabeled PSMA Inhibitors. <i>Cancers</i> , 2021, 13, 6255.	1.7	22
27	68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. <i>World Journal of Urology</i> , 2020, 38, 939-948.	1.2	23
28	Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 160-167.	3.3	25
29	68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 624-631.	3.3	26
30	The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 642-651.	3.3	29
31	Deep neural network for automatic characterization of lesions on 68Ga-PSMA-11 PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 603-613.	3.3	66
32	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1037-1042.	2.8	19
33	Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 614-623.	3.3	47
34	99mTc-MAG3 Diuretic Renography: Intra- and Inter-Observer Repeatability in the Assessment of Renal Function. <i>Diagnostics</i> , 2020, 10, 709.	1.3	5
35	PSMA-Ligand Imaging in the Diagnosis of Prostate Cancer. , 2020, , 755-763.		1
36	PSMA-negative prostate cancer and the continued value of choline-PET/CT. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 33-34.	0.3	15

#	ARTICLE	IF	CITATIONS
37	Incidental SARS-CoV-2-related findings in asymptomatic patients in [18F]-FDG-PET/CT: potential insights. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2068-2069.	3.3	11
38	Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. <i>EJNMMI Research</i> , 2020, 10, 31.	1.1	31
39	Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 29.	1.8	6
40	Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 220.	0.3	2
41	Atypical metastatic pattern of prostate cancer detected with 68Ga-PSMA PET/CT. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 85-86.	0.3	0
42	Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2289-2297.	3.3	19
43	PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges. <i>Immunotherapy</i> , 2019, 11, 1267-1271.	1.0	3
44	68Ga-PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, , .	0.3	3
45	68Ga-PSMA Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis. <i>Clinical Nuclear Medicine</i> , 2019, 44, 838-839.	0.7	1
46	68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. <i>Journal of Urology</i> , 2019, 202, 1174-1181.	0.2	33
47	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 1181-1181.	0.2	0
48	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1179-1187.	3.3	26
49	Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1373-1379.	2.8	31
50	18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1329-1334.	3.3	59
51	Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 31-37.	3.3	107
52	Feasibility and robustness of dynamic 18F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation. <i>Scientific Reports</i> , 2018, 8, 14760.	1.6	15
53	Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership. <i>Radiotherapy and Oncology</i> , 2018, 129, 387-388.	0.3	1
54	Radionuclide Therapy for Bone Metastases. <i>PET Clinics</i> , 2018, 13, 491-503.	1.5	16

#	ARTICLE	IF	CITATIONS
55	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.	1.0	25
56	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2045-2054.	3.3	116
57	Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2055-2061.	3.3	102
58	Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy. <i>Scientific Reports</i> , 2018, 8, 7201.	1.6	33
59	PSMA Theranostics: Current Status and Future Directions. <i>Molecular Imaging</i> , 2018, 17, 153601211877606.	0.7	150
60	Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1884-1897.	3.3	76
61	The Clinical Impact of Additional Late PET/CT Imaging with <sup>68</sup> Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 750-755.	2.8	105
62	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 950-959.	3.3	69
63	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268.	3.3	425
64	Intraindividual Comparison of <sup>18</sup> F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1805-1810.	2.8	91
65	Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1636-1646.	3.3	17
66	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 776-787.	3.3	124
67	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2117-2136.	3.3	234
68	PSMA Ligands for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1545-1552.	2.8	165
69	<sup>68</sup> Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. <i>Journal of Nuclear Medicine</i> , 2017, 58, 81-84.	2.8	166
70	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 79S-89S.	2.8	200
71	Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 405-418.	2.5	72
72	Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1611-1620.	3.3	143

#	ARTICLE	IF	CITATIONS
73	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>177</sup> Lu-Labeled PSMA-617. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1170-1176.	2.8	475
74	<sup>68</sup> Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 34-41.	3.3	194
75	Comparison of hybrid <sup>68</sup> Ga-PSMA PET/MRI and <sup>68</sup> Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 70-83.	3.3	148
76	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 914-920.	2.8	451
77	[ <sup>177</sup> Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 987-988.	3.3	155
78	Comparison of <sup>68</sup> Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. <i>Neuro-Oncology</i> , 2015, 17, 312-319.	0.6	64
79	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1697-1705.	2.8	332
80	The diagnostic value of PET/CT imaging with the <sup>68</sup> Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 197-209.	3.3	866
81	Novel Preclinical and Radiopharmaceutical Aspects of [ <sup>68</sup> Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. <i>Pharmaceuticals</i> , 2014, 7, 779-796.	1.7	323
82	Comparison of PET imaging with a <sup>68</sup> Ga-labelled PSMA ligand and <sup>18</sup> F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 11-20.	3.3	817
83	Radiation dosimetry and first therapy results with a <sup>124</sup> I/ <sup>131</sup> I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1280-1292.	3.3	319
84	PET/MRI with a <sup>68</sup> Ga-PSMA ligand for the detection of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1629-1630.	3.3	72
85	Hybrid Positron Emission Tomography/Magnetic Resonance Imaging with Gallium <sup>68</sup> Prostate-specific Membrane Antigen Tracer: A Next Step for Imaging of Recurrent Prostate Cancer—Preliminary Results. <i>European Urology</i> , 2013, 64, 862-864.	0.9	31